Publications by authors named "David Thorpe"

Claim this Profile
B
Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.
Benoit Trottier, Chia-Jui Yang, Dai Watanabe, Giulia Marchetti, Daniel Elbirt, David Thorpe

HIV Res Clin Pract· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies.
Andrea Antinori, Yoshiyuki Yokomaku, Hila Elinav, Hüsnü Pullukçu, Joss de Wet, David Thorpe

Infect Dis Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide-12-month results of the BICSTaR French cohort.
Laurent Hocqueloux, Fabrice Bonnet, Claudine Duvivier, Matteo Vassallo, Franck Tollinchi, David Thorpe

IJID Reg· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Traumatic Encephalopathy (CTE) and the Characterisation of "Obvious Risk of Harm": Dangerous Recreational Activity, Assumption of Risk, and Other Defences.
David Thorpe

J Law Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review: Which psycho-social-environmental factors do autistic students identify as being important for positive experiences in mainstream secondary school?
Marisa McKinlay, David Thorpe, Eilidh Cage, Catherine Grainger, Carol Jasper

Autism· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.
Andrea Antinori, Giulia Marchetti, Vincenzo Esposito, Stefano Rusconi, Diana Canetti, David Thorpe

Int J STD AIDS· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.
Yoshiyuki Yokomaku, Katsuji Teruya, Dai Watanabe, Tomoyuki Endo, Rumi Minami, David Thorpe

PLoS One· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.
David Thorpe, Marisa McKinlay, James Richards, Kate Sang, Mary E Stewart

Autism Adulthood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year.
Stefan Esser, Alexy Inciarte, Itzchak Levy, Antonella D'Arminio Monforte, John S Lambert, David Thorpe

Future Microbiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
Stefan Esser, Jason Brunetta, Alexy Inciarte, Itzchak Levy, Antonella D'Arminio Monforte, David Thorpe

HIV Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
Alexander Wong, Jason Brunetta, Joss De Wet, Ken Logue, Hugues Loemba, David Thorpe

Medicine (Baltimore)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knowledge of Chronic Traumatic Encephalopathy and Concussion Cannot Support a Negligence Suit against Major Sporting Organisations by Athletes. Or Can It?
David Thorpe

J Law Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concussion, Chronic Traumatic Encephalopathy, and the Legal Obligation of Sporting Organisations to be Informed of the Scientific Knowledge of the Day and to Warn of Material Risks.
David Thorpe

J Law Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
María Méndez, Hans Matter, Elisabeth Defossa, Michael Kurz, Sylvain Lebreton, David S Thorpe

J Med Chem· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting.
Lauren Greenberg, Lene Ryom, Gilles Wandeler, Katharina Grabmeier-Pfistershammer, Angela Öllinger, David Thorpe

J Acquir Immune Defic Syndr· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accounting for the increase of children in care in western Australia: What can a client information system tell us?
Andy Bilson, Rosemary L Cant, Maria Harries, David H Thorpe

Child Abuse Negl· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Ed L Wilkins, Calvin J Cohen, Benoit Trottier, Stefan Esser, Don E Smith, David Thorpe

AIDS Care· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responding to information about children in adversity: ten years of a differential response model in Western Australia.
Maria Harries, Rosemary L Cant, Andy Bilson, David Thorpe

Child Abuse Negl· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Georg Behrens, Bart Rijnders, Mark Nelson, Chloe Orkin, Calvin Cohen, David Thorpe

AIDS Patient Care STDS· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forward & reverse chemical genetics using SPOS-based combinatorial chemistry.
David S Thorpe

Comb Chem High Throughput Screen· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-bead and solution screening approaches for genomically derived targets. Discovery of surrogate ligands and substrates using combinatorial chemistry libraries.
David S Thorpe, Gérard Rossé, Helen Yeoman, Sydney Wilson, Patti Willson

Methods Mol Biol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis